한글목차

세계의 신경내분비종양 치료제 시장은 2030년까지 66억 달러에 달할 전망

2023년에 35억 달러로 추정되는 세계의 신경내분비종양 치료제 시장은 분석 기간인 2023-2030년에 CAGR 9.5%로 성장하며, 2030년에는 66억 달러에 달할 것으로 예측됩니다. 본 리포트에서 분석한 부문의 하나인 소마토스타틴 유사체는 CAGR 8.5%를 기록하며, 분석 기간 종료시에는 38억 달러에 달할 것으로 예측됩니다. 표적치료 분야의 성장률은 분석 기간 중 CAGR 11.5%로 추정됩니다.

미국 시장은 9억 1,740만 달러로 추정, 중국은 CAGR 8.0%로 성장 예측

미국의 신경내분비종양 치료제 시장은 2023년에 9억 1,740만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 9억 7,060만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2023-2030년의 CAGR은 8.0%입니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 7.3%와 9.0%로 예측됩니다. 유럽에서는 독일이 CAGR 3.9%로 성장할 것으로 예측됩니다.

주요 동향과 촉진요인

신경내분비종양(NET)은 전신의 신경내분비세포에서 발생하는 복잡한 암군으로, 다각적인 치료 접근이 필요합니다. NETs의 치료는 일반적으로 수술, 호르몬 요법, 화학요법, 표적 생물학적 요법의 조합으로 이루어지며, 각각의 종양 유형, 부위, 유전자 프로파일에 따라 수술, 호르몬 요법, 화학요법, 표적 생물학적 요법을 조합하여 치료합니다. 최근 NET의 생물학에 대한 이해가 크게 진전되어 새로운 표적 치료법 개발 및 진단 기술 개선이 추진되고 있습니다.

NET에 대한 연구가 진행됨에 따라 펩티드 수용체 방사성 핵종 요법(PRRT)과 새로운 소마토스타틴 유사체와 같은 새로운 치료법이 등장하여 이 희귀질환의 관리 개선에 대한 희망을 가져다주고 있습니다. 이러한 치료법 개발은 신경내분비 종양의 정확한 국소화를 보여주는 갈륨-68 도타테이트 PET 스캔과 같은 영상 진단의 혁신으로 보완되고 있습니다. 이러한 기술 발전은 진단의 정확성을 높일 뿐만 아니라 치료 효과를 효과적으로 모니터링하여 환자 관리 전략을 최적화할 수 있게 해줍니다.

신경내분비종양 치료제 시장의 성장은 NETs에 대한 인식 증가, 진단 방법의 발전, 종양 성장에 관여하는 특정 분자 경로를 표적으로 하는 혁신적인 치료법의 도입 등 여러 가지 요인에 의해 주도되고 있습니다. 또한 NETs의 유병률 증가와 세계 인구의 고령화는 효과적인 치료법에 대한 수요 증가에 기여하고 있습니다. 제약사들은 보다 효과적이고 독성이 낮은 치료법 개발에 지속적으로 투자하고 있으며, 규제 당국은 미충족 의료 수요를 충족하는 의약품의 조기 승인 절차를 통해 이러한 노력을 지원하고 있습니다.

조사 대상 기업의 예(총 86건)

• AbbVie, Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Co., Ltd.
• Eli Lilly and Company
• Exelixis, Inc.
• HUTCHMED
• Ipsen Pharma
• Isotopen Technologien MA1/4nchen
• Lantheus Holdings, Inc.
• Merck & Co., Inc.
• Neurocrine Biosciences, Inc.
• Novartis AG
• Pfizer, Inc.
• Sun Pharmaceutical Industries Ltd.

목차

제1장 조사 방법

제2장 개요

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 세계 시장의 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 기타 유럽
• 아시아태평양
• 기타 지역

제4장 경쟁

영문목차

Global Neuroendocrine Tumors Therapeutics Market to Reach US$6.6 Billion by 2030

The global market for Neuroendocrine Tumors Therapeutics estimated at US$3.5 Billion in the year 2023, is expected to reach US$6.6 Billion by 2030, growing at a CAGR of 9.5% over the analysis period 2023-2030. Somatostatin Analogs, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$3.8 Billion by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 11.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$917.4 Million While China is Forecast to Grow at 8.0% CAGR

The Neuroendocrine Tumors Therapeutics market in the U.S. is estimated at US$917.4 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$970.6 Million by the year 2030 trailing a CAGR of 8.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.3% and 9.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Key Trends and Drivers

Neuroendocrine tumors (NETs) represent a complex group of cancers arising from neuroendocrine cells throughout the body, requiring multifaceted treatment approaches. These tumors vary widely in their behavior, often being slow-growing and asymptomatic, which complicates early diagnosis and treatment. The management of NETs typically involves a combination of surgery, hormonal therapy, chemotherapy, and targeted biological therapies, each tailored to the tumor type, location, and genetic profile. Recent years have seen significant advancements in the understanding of NET biology, driving the development of new targeted therapies and improving diagnostic techniques.

As research into NETs advances, new therapeutic options such as peptide receptor radionuclide therapy (PRRT) and novel somatostatin analogs have emerged, offering hope for improved management of this rare condition. The development of these therapies is complemented by innovations in diagnostic imaging, such as Gallium-68 DOTATATE PET scans, which provide precise localization of neuroendocrine tumors. These technological advancements not only enhance the accuracy of diagnosis but also allow for the effective monitoring of treatment response, thereby optimizing patient management strategies.

The growth in the neuroendocrine tumors therapeutics market is driven by several factors, including increased awareness of NETs, advancements in diagnostic methods, and the introduction of innovative treatments that target specific molecular pathways involved in tumor growth. Additionally, the rising prevalence of NETs and the aging global population contribute to the expanding demand for effective treatments. Pharmaceutical companies continue to invest in the development of more efficacious and less toxic therapeutic options, while regulatory agencies support these initiatives through accelerated approval processes for drugs that address unmet medical needs in the NET patient community.

Select Competitors (Total 86 Featured) -

• AbbVie, Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Co., Ltd.
• Eli Lilly and Company
• Exelixis, Inc.
• HUTCHMED
• Ipsen Pharma
• Isotopen Technologien MA1/4nchen
• Lantheus Holdings, Inc.
• Merck & Co., Inc.
• Neurocrine Biosciences, Inc.
• Novartis AG
• Pfizer, Inc.
• Sun Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Neuroendocrine Tumors Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence and Awareness of Neuroendocrine Tumors
  • Advances in Molecular Diagnostics Enhancing Treatment Selection
  • New Developments in Targeted Radionuclide Therapies
  • Expanding Use of Genomic Profiling in Therapy Choices
  • Impact of Immuno-Oncology on NETs Treatment
  • Growing Importance of Multidisciplinary Care Teams
  • Increasing Number of FDA Approvals for Novel Therapies
  • Innovations in Drug Delivery Systems
  • Clinical Trials Addressing Unmet Needs in NET Treatment
  • Economic Impacts of Long-Term Cancer Treatment
  • Partnerships Between Biotech Firms and Academic Centers
  • Regulatory Support for Accelerated Drug Development
  • Investment Trends in Oncology Research
  • Demand for Personalized Medicine and Companion Diagnostics
  • Impact of Aging Populations on Cancer Prevalence
  • Challenges in Managing Chronic and Late-Stage NETs
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Neuroendocrine Tumors Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Neuroendocrine Tumors Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Somatostatin Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Somatostatin Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Somatostatin Analogs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Product Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Product Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Other Product Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hospital End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hospital End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Hospital End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 23: USA Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: USA 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 29: Canada Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: Canada Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: Canada 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• JAPAN
  • Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 35: Japan Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Japan Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Japan 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• CHINA
  • Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 41: China Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: China Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: China 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
  • TABLE 44: China Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: China 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• EUROPE
  • Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 47: Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 48: Europe Historic Review for Neuroendocrine Tumors Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Europe 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• FRANCE
  • Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 56: France Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: France Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: France 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
  • TABLE 59: France Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: France 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• GERMANY
  • Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Germany Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: Germany 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Italy Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Italy 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 74: UK Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: UK Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: UK 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
  • TABLE 77: UK Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Rest of Europe Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: Rest of Europe 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
  • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Rest of Europe Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: Rest of Europe 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Asia-Pacific Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: Asia-Pacific 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
  • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Asia-Pacific Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Asia-Pacific 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Rest of World Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Rest of World 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
  • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Rest of World Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Rest of World 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION